Oxford Academic Health Science Network

What Oxford Academic Health Science Network does

Health Innovation Oxford & Thames Valley (HIOTV, formerly Oxford Academic Health Science Network / Oxford AHSN) is an NHS-hosted innovation adoption body that finds, develops and supports the spread of evidence-based healthcare innovation across the NHS in the Thames Valley and nationally. Established in 2013 as one of 15 Academic Health Science Networks, rebranded in line with the national rebrand to Health Innovation Networks, and hosted by Oxford University Hospitals NHS Foundation Trust, HIOTV is principally commissioned by NHS England and the Office for Life Sciences (OLS) and sits within a tightly defined national network of 15 such bodies.

Its work is organised around four core programmes: Patient Safety and Clinical Improvement (PSC), Clinical Innovation Adoption (CIA), Strategic and Industry Partnerships (SIP), and Community Involvement and Workforce Innovation (CIWI). These programmes deliver a portfolio of NHS clinical priorities (maternity and neonatal safety, deterioration management including NEWS2, RESTORE2, ReSPECT and Martha's Rule, medicines safety, respiratory, cardiovascular, cancer, healthy ageing) and a suite of adoption services for healthcare innovators. Technical capability centres on the proprietary Lean Assessment Process (LAP) used for real-world feasibility evaluation across multiple NHS trusts, externally-developed Strategyzer methodology workshops (Value Proposition Canvas and Business Model Canvas) for innovator business model support, and a health economic evaluation function led by a dedicated Head of Health Economics and Methodology.

Revenue is derived principally from NHS England and OLS commissioning, supplemented by programme-specific co-funding (notably the £10 million two-year Respiratory Transformation Partnership with OLS, NHS England, AstraZeneca, Chiesi and others) and grants (Innovate UK, NIHR, SBRI). Four primary customer segments are served: NHS organisations (Trusts, ICBs, primary care, secondary care), healthcare innovators and SMEs (UK and EU), life sciences industry partners (AstraZeneca, Chiesi, Perspectum, Ufonia, Presymptom Health, RMD-Health), and academic and patient/public communities. There is no commercial price list; engagement is initiated through a standard Health Innovation Network engagement form with commissioning-aligned paid and unpaid support.

Name

Oxford Academic Health Science Network

Legal name

Health Innovation Oxford and Thames Valley

Website

https://healthinnovationoxford.org

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Health Innovation Oxford & Thames Valley is an NHS-hosted innovation adoption body, commissioned by NHS England and the Office for Life Sciences, that accelerates uptake of evidence-based healthcare innovations across NHS Trusts, industry and academic partners in the Thames Valley and nationally.

Ownership category

akta.pro rank

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. NHS England and Office for Life Sciences (OLS) commissioning: Core funding comes from public sector commissioning. The organisation is 'part of a national network commissioned by NHS England and the Office for Life Sciences (OLS) and are hosted by Oxford University Hospitals (OUH).' Operates as one of 15 Health Innovation Networks in England delivering the OLS commission.
2. Co-funded programme grants (e.g., OLS/Innovate UK co-funding): Receives co-funding for specific initiatives — for example, 'Oxford AHSN and Perspectum Diagnostics enabled by Office for Life Sciences and Innovate UK funding to collect supporting evidence on the impact of LiverMultiScan in the NHS.' The Respiratory Transformation Partnership receives £10 million over two years from OLS, NHS England and four industry partners (AstraZeneca, Chiesi, etc.).
3. Industry partnership and consultancy: Strategic and Industry Partnerships (SIP) programme works with companies to provide signposting, real-world validation, adoption support, consultancy and advice. The organisation provides paid and unpaid support services to industry partners and life sciences companies.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Core offering

Health Innovation Oxford & Thames Valley (formerly Oxford AHSN) is a publicly commissioned NHS England/Office for Life Sciences body that accelerates the adoption of evidence-based healthcare innovations — including AI, medical devices, novel medicines, diagnostics and digital technologies — across the NHS. It sells innovation adoption support, real-world evaluation (via its proprietary Lean Assessment Process), health economic analysis, funding application support, and convenes programmes such as the Elective Care Respiratory Pathways and the Perinatal Culture and Leadership Programme. Services are delivered to NHS organisations, life sciences industry partners (including AstraZeneca, Chiesi), academic institutions and healthcare innovators in the UK and EU.

Product overview

Health Innovation Oxford & Thames Valley (formerly Oxford AHSN) is not a single software product but a regional innovation adoption network that delivers a portfolio of programmes and services to the NHS, life sciences industry, universities and patients across the Thames Valley. Its work is structured as a platform of four core programmes — the Patient Safety and Clinical Improvement (PSC) programme, the Clinical Innovation Adoption (CIA) programme, the Strategic and Industry Partnerships (SIP) programme, and the Community Involvement and Workforce Innovation (CIWI) team — each of which acts as a delivery vehicle for a set of named clinical projects, evaluation studies, toolkits, guidelines, and digital innovations (e.g. Sleepio, CardioSignal, e-Stroke, GRASP-OsteoporosisRx, Soluble FLT/PlGF testing, the Elective Care Respiratory Pathways programme and the Maternity Clinical Network Guidelines). It is commissioned by NHS England and the Office for Life Sciences, and is hosted by Oxford University Hospitals NHS Foundation Trust, sitting within a national network of 15 Health Innovation Networks.

Differentiator

Problem solved

Functional benefit

Products and services

• Patient Safety and Clinical Improvement programme (Oxford PSC) Builds a culture of safety, continuous learning and improvement across the NHS in line with national, regional and local priorities; the largest patient safety initiative in NHS history, coordinated by NHS England and delivered through the 15 Health Innovation Networks.
• Clinical Innovation Adoption (CIA) programme Implements evidence-based innovation across the NHS, improving patient outcomes and reducing NHS costs, with focus areas including national programmes, local programmes, industry support, medicines optimisation, digital health/AI, cardiovascular disease, cancer, healthy ageing, workforce support and heart failure.
• Strategic and Industry Partnerships (SIP) programme Builds evidence for innovation with companies and other partners to accelerate health and economic gains; delivers the four OLS-commissioned functions of identifying regional priorities, signposting and supporting innovators, real-world validation, and adoption and spread of innovations.
• Community Involvement and Workforce Innovation (CIWI) team Ensures patients, the public, carers, communities and the workforce are represented and involved in the organisation's work, and supports colleagues to evaluate impact of programmes and understand what matters to public, patients, and staff.
• Elective Care Respiratory Pathways (ECRP) programme National NHS England-commissioned programme led by Health Innovation Oxford and Thames Valley to improve elective pathways for sleep, breathlessness and chronic cough; includes a 27-trust vanguard cohort, an implementation toolkit, and neighbourhood left-shift work, co-led with Health Innovation Yorkshire & Humber, Imperial College Health Partners, PCRS and the CLEAR programme.
• Perinatal Culture and Leadership Programme (PCLP) Supports maternity and neonatal teams in strengthening culture as a foundation for safer, more equitable care, through facilitated coaching, structured tools such as MOMENTS, data-driven priorities and culture-coach roles.
• Cervical Length Ultrasound Education pilot Pilot programme delivering cervical length ultrasound education to obstetrics and gynaecology resident doctors across John Radcliffe Hospital and Stoke Mandeville Hospital, aimed at reducing risk of preterm birth.
• Strategyzer methodology workshops for healthcare innovators Workshops using the Strategyzer Value Proposition Canvas and Business Model Canvas frameworks, run for healthcare innovators at all stages of product development with healthcare-specific customisation.
• Real-world evaluation service (Lean Assessment Process) Real-world validation of healthcare innovations in NHS settings using the proprietary Lean Assessment Process (LAP) methodology, including semi-structured clinician interviews and health economic analysis, as demonstrated in studies such as InfectiClear Rapid, RMD-Health rheumatology tool and LiverMultiScan.
• Innovator engagement and funding support service Strategic and Industry Partnerships support for innovators, including innovation signposting, toolkits for healthcare innovators, real-world evaluation, spread and adoption, funding application support, and consultancy and advice.
• Heart failure adoption programme Adoption programme supporting improvements in heart failure care across primary and secondary care, with learning bites for clinicians.
• Cardiovascular disease adoption programme (AF, CardioSignal, virtual TIA clinics) Adoption programme covering detection and management of atrial fibrillation (including the CardioSignal project and AF Champions) and evaluation of virtual TIA outpatient clinics.
• Cancer adoption programme Adoption programme covering digital innovation in prostate cancer care, innovation in prostate surgery, and prostate cancer webinar resources.
• Healthy ageing programme (GRASP-OsteoporosisRx) Adoption programme featuring the GRASP-OsteoporosisRx tool to optimise osteoporosis treatment in primary care and reduce fragility fractures, with project resources hosted by the organisation.
• Digital health / AI adoption programme Adoption programme evaluating and scaling digital health and AI technologies such as e-Stroke AI, Sleepio and digital solutions in mental health.
• Medicines optimisation programme (Polypharmacy, repeat prescribing, TVMOC) Adoption programme including Polypharmacy: getting the balance right, Improving repeat prescribing, and the Thames Valley Medicines Optimisation Collaborative.
• Workforce support programme (Masters-level module) Adoption programme including a Masters-level module for healthcare innovators (Adopting Innovation and Managing Change in Healthcare Settings).
• Avoiding Brain Injury in Childbirth (ABC) programme National programme within the Maternity and Neonatal workstream of the Patient Safety programme, aimed at reducing brain injury in childbirth through improved intrapartum care.
• National Maternity Early Warning Score (MEWS) tool Standardised national tool for the early detection of deterioration in pregnant and postpartum women, implemented through the Maternity and Neonatal workstream.
• Quality Improvement (QI) programme Capacity-and-capability-building programme covering QI essentials, the model for improvement, measurement for improvement, and bronze-level QI and Human Factors training.
• Medicines Safety programme Workstream of the Patient Safety programme supporting safer use of medicines, including work to reduce inappropriate high-dose opiate prescriptions for non-cancer pain.
• Patient Safety Incident Response Framework (PSIRF) support National NHS framework for responding to patient safety incidents, supported through the Patient Safety programme with local implementation resources.
• NEWS2 and RESTORE2 deterioration tools programme National Early Warning Score (NEWS2) for acute settings and RESTORE2 for care homes, with primary care, care home and acute resources, used to detect and respond to patient deterioration.
• ReSPECT programme Patient-held document used to record personalised recommendations about clinical care and escalation in the event of deterioration, supported by the Deterioration workstream.
• Martha's Rule programme Mechanism enabling patients, families and staff to request an urgent review by a different clinical team if they are concerned about deterioration, supported through the Deterioration workstream.
• Transforming Wound Care programme Patient Safety sub-programme focused on improving wound care practice and outcomes in the NHS.
• Health Innovation Oxford & Thames Valley Maternity Clinical Network Guidelines Region-wide maternity and neonatal clinical guidelines covering topics such as antenatal corticosteroids, cervical length, antenatal reduced fetal movements, CTG interpretation, induction of labour, IUGR, magnesium sulphate, oxytocin, perinatal palliative care, placental histology, preterm labour, rhesus bundle, and soluble FLT/PlGF ratio.
• Net zero / environmental sustainability programme Strategic and Industry Partnerships programme activity including 'Toolkit: Better outcomes for asthma patients and the planet', a Net zero guide for innovators, and the organisation's own carbon reduction plan.
• Medicines Safety Improvement Programme (Learning Disability) System mapping and action planning work in collaboration with the NHS Thames Valley Integrated Care Board to reduce high-risk prescribing of psychotropic medicines in people with a learning disability, as part of the NHS Medicines Safety Improvement Programme.

Quantifiable outcome

• £10 million over two years for the Respiratory Transformation Partnership (RTP) programme
• +5 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability18 records

Feature4 records

Partnerships

24 partnerships are on record, tiered flagship, core and minor.

• NHS EnglandflagshipStrategic or Co-development PartnerNHS England is one of the two principal commissioners of Health Innovation Oxford & Thames Valley alongside the Office for Life Sciences. The organisation is part of a national network of 15 Health Innovation Networks commissioned by NHS England. NHS England also commissions specific programmes such as the Perinatal Culture and Leadership Programme (2024–26) and the national Elective Care Respiratory Pathways programme.
• Office for Life Sciences (OLS)flagshipStrategic or Co-development PartnerCo-commissioner of Health Innovation Oxford & Thames Valley alongside NHS England. OLS funds the Strategic and Industry Partnerships (SIP) programme as part of its four core functions (identifying need, signposting, real-world validation, adoption and spread). Co-funded the Respiratory Transformation Partnership (£10m) and co-funded initiatives such as Perspectum Diagnostics LiverMultiScan evidence generation with Innovate UK.
• Oxford University Hospitals (OUH) NHS Foundation TrustflagshipStrategic or Co-development PartnerHost organisation for Health Innovation Oxford & Thames Valley, which is part of OUH and subject to its policies and procedures (including the OUH privacy policy). OUH is also a key clinical partner — e.g., cervical length ultrasound education pilot delivered across John Radcliffe Hospital.
• Health Innovation Yorkshire and Humber (HIYH)coreStrategic or Co-development PartnerLead delivery partner on the national Elective Care Respiratory Pathways (ECRP) programme, leading the 'Scaling breathlessness pathways in primary and secondary care' workstream. Co-delivers the programme alongside HIOTV, ICHP, PCRS and CLEAR.
• Imperial College Health Partners (ICHP)coreStrategic or Co-development PartnerLead delivery partner on the national Elective Care Respiratory Pathways (ECRP) programme, leading the 'Optimising chronic cough management across the patient pathway' workstream.
• Primary Care Respiratory Society (PCRS)coreStrategic or Co-development PartnerLead delivery partner on the national ECRP programme, jointly with the national CLEAR programme, leading the 'Neighbourhood extension' workstream.
• CLEAR programme (national)coreStrategic or Co-development PartnerJoint lead (with PCRS) of the 'Neighbourhood extension' workstream of the ECRP national programme. CLEAR is described as 'Empowering staff to innovate care'.
• AstraZenecacoreStrategic or Co-development PartnerOne of four named industry partners funding the Respiratory Transformation Partnership (RTP) with a total of £10 million over two years alongside OLS and NHS England. RTP focuses on improving care for people with asthma, COPD and other respiratory conditions.
• ChiesicoreStrategic or Co-development PartnerOne of four named industry partners co-funding the Respiratory Transformation Partnership (RTP), a national collaboration to improve respiratory care.
• British Thoracic Society (BTS)minorGTM or Marketing PartnerSupporting partner of the ECRP national programme. HIOTV leads a session at the British Thoracic Society Summer Meeting (9 July 2026) on the elective care respiratory programme.
• Association for Respiratory Technology & Physiology (ARTP)minorGTM or Marketing PartnerSupporting partner of the ECRP national programme. Logged as an organisational logo on the ECRP page.
• GIRFT (Get It Right First Time)minorGTM or Marketing PartnerSupporting partner of the ECRP national programme. Logged as an organisational logo on the ECRP page.
• NCIMI (National Consortium of Intelligent Medical Imaging)minorStrategic or Co-development PartnerPartnership improved patient outcomes and generated economic growth through adoption of AI medical imaging. Referenced as a case study on the economic growth case studies page.
• Buckinghamshire, Oxfordshire and Berkshire West Integrated Care Board (BOB ICB)coreStrategic or Co-development PartnerValued, trusted, critically important partner of the ICB. HIOTV works with the ICB to deliver sustainable pathways of care and supports the ICB's medicines safety improvement programme (e.g., psychotropic medicines prescribing for people with a learning disability).
• Buckinghamshire Healthcare NHS TrustcoreStrategic or Co-development PartnerCollaboration on the cervical length ultrasound education pilot (with OUH and HIOTV), shortlisted for HSJ Patient Safety Awards 2026. Dr Aparna Reddy, Consultant in Obstetrics and Fetal Medicine at Buckinghamshire Healthcare, is a named clinical lead.
• University of OxfordcoreStrategic or Co-development PartnerLong-term research partner. Professor Sarah Pendlebury (Professor of Medicine and Old Age Neuroscience) is a named collaborator on AI dementia diagnostic tool evaluation. The Oxford academic and clinical ecosystem underpins much of HIOTV's innovation activity.
• NHS Thames Valley Integrated Care BoardcoreStrategic or Co-development PartnerPartner on the NHS Medicines Safety Improvement Programme, with system mapping and action planning to address psychotropic prescribing for people with a learning disability in Thames Valley. Orla Macdonald, Consultant Pharmacist, is a named partner.
• UfoniaminorStrategic or Co-development PartnerHealth-tech startup supported through early evidence generation and health economic evaluation of 'Dora', Ufonia's AI clinical assistant. Aisling Higham (Medical Director, Ufonia) is a named partner on the homepage.
• Oxford Health NHS Foundation TrustcoreStrategic or Co-development PartnerCollaboration with the HIOTV patient safety team on ward-level culture change and patient safety improvements. Dr Karl Marlowe (Chief Medical Officer) is a named partner on the homepage.
• ABHI (Association of British HealthTech Industries)minorGTM or Marketing PartnerJoint conference partnership — Dr James Rose (Director of Strategic and Industry Partnerships at HIOTV) joins ABHI's digital health conference (7 October 2026) as a faculty speaker.
• Perspectum DiagnosticsminorStrategic or Co-development PartnerOxford AHSN and Perspectum Diagnostics were enabled by Office for Life Sciences and Innovate UK funding to collect supporting evidence on the impact of LiverMultiScan in the NHS.
• Presymptom HealthminorStrategic or Co-development PartnerHIOTV performed a feasibility study of InfectiClear Rapid (a rapid molecular diagnostic for early rule-out of infection) using its Lean Assessment Process (LAP) methodology, with semi-structured interviews across nine NHS trusts.
• RMD-HealthminorStrategic or Co-development PartnerHIOTV conducted a feasibility study of RMD-Health's machine learning-based risk stratification tool for the rheumatology referral pathway, gathering insights from GPs, rheumatology registrars and consultants to assist RMD-Health in finalising tool functionality.
• South East AHSNs (Health Innovation Networks)coreStrategic or Co-development PartnerCollaboration with other South East Health Innovation Networks to support adoption of home testing to identify diabetic patients at risk of chronic kidney disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Innovate UK: The UK's national innovation agency, which co-funds healthcare evidence-generation initiatives (e.g. Perspectum LiverMultiScan with HIOTV) and operates adjacent funding competitions (Biomedical Catalyst, Smart Grants) for the same health-tech innovator audience.
• Cell and Gene Therapy Catapult: An Innovate UK-created technology and innovation Catapult focused on cell and gene therapy adoption into the NHS and industry; comparable in being a publicly-funded intermediary accelerating UK health innovation into clinical and commercial use.
• NIHR (National Institute for Health and Care Research): The UK government's main funder of clinical, applied health and social care research; HIOTV directly routes innovators to NIHR funding streams (i4i, HSDR, EME, HTA) and shares engagement data, making NIHR both a partner and a broader incumbent shaping the same NHS innovation pipeline.

Direct peers

• Cambridge University Health Partners: An Academic Health Science Centre / equivalent partnership in the East of England that, like HIOTV, links the University of Cambridge and major NHS trusts to translate research and innovation into clinical adoption.
• UCLPartners: An academic health science partnership covering North Thames with a comparable remit to accelerate the spread of innovation across the NHS; operates a similar innovator-support and adoption model anchored to a major university hospital cluster.
• Health Innovation Yorkshire & Humber: One of the 15 Health Innovation Networks in England and a co-delivery partner on HIOTV's national Elective Care Respiratory Pathways programme, leading the breathlessness workstream — directly comparable in mandate, commissioning structure and service portfolio.
• Imperial College Health Partners: A fellow Health Innovation Network (London) co-delivering the ECRP national programme with HIOTV and operating the same NHS England/OLS-commissioned innovation adoption, patient safety and industry partnership remit across a different geography.
• SBRI Healthcare: An NHS England-funded programme that awards contracts to health tech innovators to solve specific NHS challenges; HIOTV actively supports companies applying to SBRI competitions, making it a directly comparable funding/adoption channel for the same innovator customers.
• Health Innovation Manchester (formerly Greater Manchester AHSN): Another of the 15 HINs, hosted by a Manchester NHS trust and delivering the same innovation adoption, clinical evaluation and industry partnership services to NHS, academia and industry in the North West — a like-for-like comparator on commissioning model and service mix.

Regional players

• MedCity: A London-focused life sciences cluster organisation promoting investment, industry partnerships and NHS access; comparable in mission (connecting innovators, NHS and industry) but geographically focused on the Golden Triangle/London rather than the Thames Valley.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/OxfordAHSN
• YouTubeyoutube.com/@healthinnovox
• LinkedInlinkedin.com/company/oxford-ahsn
• Facebookfacebook.com/oxfordahsn

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxford Academic Health Science Network